Trial Profile
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Moxifloxacin (Primary)
- Indications Endophthalmitis
- Focus Registrational; Therapeutic Use
- 25 Jul 2023 Planned initiation date changed from 1 Jan 2023 to 1 Jun 2024.
- 31 Dec 2022 Planned number of patients changed from 15000 to 60000.
- 22 Aug 2022 Planned initiation date changed from 1 Jul 2023 to 1 Jan 2023.